Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to consider goals and applications for NASH Biomarkers.
Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss Five Key Takeaways in two recent presentations on NITs. He challenges the group to reconsider what NIT (and testing) NASH Best Practices should become.
Quentin Anstee joins the Surfers (including Stephen Harrison) to share lessons about the proper use of non-invasive tests in the clinical trial process and to explore implications for best practices and future research or research.
Surfing the NASH Tsunami shares Dr. Mazen Noureddin’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD pathophysiology and NASH epidemiology. After this, he answers questions from Roger Green.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green all discuss the role that combination NASH drugs and greater population diversity in clinical trials will strengthen NASH drug development.
Stephen Harrison discusses the state of NASH Drug Development in 2022 with focus on the key steps on the pathway and how late-stage NASH drugs are progressing
Stephen Harrison leads a review of drug development and where we are in the NASH pipeline as Jörn Schattenberg, Louise Campbell and Roger Green lend their own perspectives and ask questions
Professor Ian Rowe and scientist/entrepreneur Rachel Zayas join the Surfers to preview the 5th Global NASH Congress. This conversation focuses on a range of topics.
Ian Rowe and Rachel Zayas join the Surfers to help Surfing the NASH Tsunami preview the 5th Global NASH Congress.
As Jörn Schattenberg joins the permanent Surfing crew, he sits with Louise Campbell and Roger Green to share his background and focus and to discuss where SurfingNASH.com will take NASH Tsunami in its third full year.
